NantHealth’s Cancer Therapy Pre-Authorization Platform Eviti Connect® Starts 2020 Strong with Two Expanded Programs

Continued Relationships with Health Insurers Reflect the Need for High-quality, High-value Care as Cancer Treatments Become Increasingly Complex

CULVER CITY, Calif.–(BUSINESS WIRE)–NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, announced today two expanded programs with Eviti Connect®, NantHealth’s healthcare payer solution and provider decision support software. A leading U.S. Medicaid health plan expanded its coverage and one of the largest non-profit, rural health plans in the country offering coverage for 165,000 members will continue to drive high-value oncological care with Eviti Connect.

Eviti Connect streamlined the pre-authorization process for cancer treatments and reduced denials and appeals for this leading U.S. Medicaid health plan, while providing oncologists in their network with access to a comprehensive library of evidence-based treatment options for optimal decision making. For one of the largest non-profit rural health plans in the country, Eviti Connect improved consistency in the use of evidence-based medicine, simplified processes, and streamlined treatment approvals that enable cancer patients to begin treatment quickly and efficiently.

“Implementation of the Affordable Care Act has resulted in a much more diverse Medicaid population,” said Dr. William Flood, Chief Medical Officer for Eviti at NantHealth. “Medicaid plans now must address more members and a higher prevalence of cancer. Eviti’s comprehensive evidence-based medical library and experienced oncology medical staff enables Medicaid programs to evolve and meet these new challenges quickly.”

The Medicaid health plan experienced compelling results in their two-state pilot program. During the two-year pilot, which covered approximately 250,000 members, the insurer noted a significant improvement in the use of evidence-based medicine for member oncology care as a result of providers submitting treatment requests via Eviti Connect. The successful pilot led the insurer to expand the program from two to 10 U.S. states.

For Eviti Connect to continue to help assure quality, high-value care for members with cancer, the non-profit, rural health plan signed a three-year renewal agreement. Under terms of the agreement, the health plan’s provider network will continue to benefit from Eviti Connect decision support solution, which includes evidence-based treatment regimens, condition-specific clinical trial options, and the potential for more efficient preauthorization and expedited reimbursement.

“This renewal of Eviti Connect by a large health plan demonstrates our continued leadership in delivering solutions that align the priorities of physicians, patients, and payers at the moment of clinical prescribing to promote the best care for patients,” said Mark Mozley, Senior Vice President, Global Sales & Marketing, NantHealth. “We are pleased to continue this relationship momentum and support our clients’ goals to exceed industry standards for the authorization of oncology care.”

NantHealth’s Eviti Connect is a web-based healthcare payer solution that electronically connects health plans and oncology practices for the authorization of treatment plans in near real-time. Eviti Connect reduces the administrative time involved in obtaining authorizations at the drug level, assures appropriate reimbursement at the regimen level, and validates cancer treatment options overall. It also provides the ability to have peer-to-peer conversations between prescribing oncologists and NantHealth oncologists.

About NantHealth, Inc.

NantHealth, a member of the NantWorks ecosystem of companies, provides leading solutions across the continuum of care for physicians, payers, patients and biopharmaceutical organizations. NantHealth enables the use of cutting-edge data and technology toward the goals of empowering clinical decision support and improving patient outcomes. NantHealth’s comprehensive product portfolio combines the latest technology in payer/provider platforms that exchange information in near-real time (NaviNet and Eviti), and molecular profiling services that combine comprehensive DNA & RNA tumor-normal profiling with pharmacogenomics analysis (GPS Cancer®). For more information, please visit nanthealth.com or follow us on Twitter, Facebook and LinkedIn.

This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. Risks and uncertainties include, but are not limited to: our ability to successfully integrate a complex learning system to address a wide range of healthcare issues; our ability to successfully amass the requisite data to achieve maximum network effects; appropriately allocating financial and human resources across a broad array of product and service offerings; raising additional capital as necessary to fund our operations; achieving significant commercial market acceptance for our sequencing and molecular analysis solutions; establish relationships with key thought leaders or payers’ key decision makers in order to establish our sequencing and molecular analysis solutions as a standard of care for patients with cancer; our ability to grow the market for our systems infrastructure and applications; successfully enhancing our systems infrastructure and applications to achieve market acceptance and keep pace with technological developments; customer concentration; competition; security breaches; bandwidth limitations; our ability to continue our relationship with NantOmics; our ability to obtain regulatory approvals; dependence upon senior management; the need to comply with and meet applicable laws and regulations; unexpected adverse events; clinical adoption and market acceptance of our sequencing and molecular analysis solutions; and anticipated cost savings. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our reports filed with the Securities and Exchange Commission.

Contacts

NantHealth
Jen Hodson

[email protected]
562-397-3639